世界の幹細胞療法市場:種類別(同種、自家)、細胞源別、治療用途別

◆英語タイトル:Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

MarketsandMarketsが発行した調査報告書(BT5049-22)◆商品コード:BT5049-22
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2022年9月17日
◆ページ数:160
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

MarketsandMarkets社の最新調査レポートによると、世界の幹細胞療法市場規模は、2022年257百万ドルから2027年558百万ドルまで年平均16.8%成長すると推定されます。当書は、幹細胞療法の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(同種幹細胞療法、自家幹細胞療法)分析、細胞源別(脂肪組織由来MSC、骨髄、胎盤/臍帯、その他)分析、治療用途別(筋骨格、創傷、手術、心血管、神経)分析、地域別(北米、ヨーロッパ、アジア太平洋、その他地域)分析、競争状況、企業情報などについて総合的にまとめています。なお、当書に掲載されている企業情報には、Smith+Nephew (UK)、MEDIPOST Co. Ltd. (South Korea) 、Anterogen Co. Ltd. (South Korea)、CORESTEM (South Korea) 、Pharmicell Co. Ltd. (South Korea)、NuVasive Inc. (US)、RTI Surgical (US)、AlloSource (US)、JCR Pharmaceuticals Co. Ltd. (Japan)、Takeda Pharmaceutical Company Limited (Japan) などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の幹細胞療法市場規模:種類別
- 同種幹細胞療法の市場規模
- 自家幹細胞療法の市場規模
・世界の幹細胞療法市場規模:細胞源別
- 脂肪組織由来MSCによる幹細胞療法の市場規模
- 骨髄由来MSCによる幹細胞療法の市場規模
- 胎盤/臍帯由来MSCによる幹細胞療法の市場規模
- その他細胞源による幹細胞療法の市場規模
・世界の幹細胞療法市場規模:治療用途別
- 筋骨格用幹細胞療法の市場規模
- 創傷用幹細胞療法の市場規模
- 手術用幹細胞療法の市場規模
- 心血管用幹細胞療法の市場規模
- 神経用幹細胞療法の市場規模
・世界の幹細胞療法市場規模:地域別
- 北米の幹細胞療法市場規模
- ヨーロッパの幹細胞療法市場規模
- アジア太平洋の幹細胞療法市場規模
- その他地域の幹細胞療法市場規模
・競争状況
・企業情報

“世界の幹細胞療法市場は、2022年2億5700万米ドルから2027年5億5800万米ドルまで、年平均成長率16.8%で成長すると予測”
幹細胞療法に関する臨床試験の件数が増加していることから、複数の企業が再生医療の開発に注力しています。臨床試験の数が増加しているのは、細胞ベースの治療法の研究開発に対する政府や官民の投資の増加、支持的な規制の枠組み、再生医療の研究開発におけるFDAによる迅速な承認規定によるところが大きいです。

“予測期間中、幹細胞療法市場の種類別成長率は同種幹細胞療法が最も高くなる見込み”
幹細胞療法市場は同種幹細胞療法と自家幹細胞療法に区分されます。同種幹細胞療法分野が幹細胞療法市場で最大のシェアを占めています。同種幹細胞療法に使用される幹細胞は、対象となる患者以外から採取されます。同種幹細胞療法では、1つの細胞源から多くの投与量を得ることができるため、同種幹細胞療法は経済的に実行可能であり、時間もかかりません。さらに、同種幹細胞療法は自家幹細胞療法に比べ、生産プロセスのスケールアップが容易です。現在、世界中で10種類以上の同種幹細胞療法が承認され、商品化されています。

“骨髄由来MSCsセグメントが最も高いCAGRを獲得”
細胞源に基づき、世界の幹細胞療法市場は脂肪組織由来MSC(間葉系幹細胞)、骨髄由来MSC、胎盤/臍帯由来MSC、その他の細胞源に区分されます。骨髄由来間葉系幹細胞は、幹細胞療法において最も好まれるタイプです。骨髄由来間葉系幹細胞は、入手が容易で、試験管内での処理が少なくて済み、自家および同種幹細胞療法に用いることができます。過去10年間、幹細胞療法市場では、免疫不全症候群、ヘモグロビン血症、代謝性疾患など、様々な治療用途の骨髄由来幹細胞製品に対する高い需要が見られました。これがこのセグメントの成長に大きく貢献しています。

“アジア太平洋: 幹細胞療法市場で最も急成長している地域”
幹細胞療法市場は、北米、欧州、アジア太平洋地域、RoWに区分されます。アジア太平洋地域の幹細胞療法市場は、予測期間中に最も高いCAGRで成長する見込みです。インドでは神経変性疾患の患者数が増加しており、幹細胞療法製品の市場成長を牽引しています。また、韓国では幹細胞療法製品に対する政府の支援が充実しており、アジア太平洋地域の幹細胞療法市場の成長を後押ししています。

本レポートのために実施した一次インタビューは以下のように分類されます:
- 回答者別 供給側80%、需要側20%
- 役職別 Cレベル25%、Dレベル20%、その他55%
- 地域別 北米 -50%、ヨーロッパ -20%、アジア太平洋地域 -20%、RoW -10%

レポート掲載企業リスト
• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCRファーマ株式会社(日本)
• 武田薬品工業株式会社(日本)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

調査対象範囲
本レポートは幹細胞療法市場の詳細な情報を提供します。種類、治療用途、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最新動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、幹細胞療法市場全体とそのセグメントの売上高に最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、動向、機会、課題に関する情報を提供することを可能にします。

❖ レポートの目次 ❖

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 STUDY SCOPE 27
FIGURE 1 STEM CELL THERAPY MARKET 27
1.3.1 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH APPROACH 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS 33
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 34
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 34
2.3 GROWTH FORECAST 36
FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027) 36
FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 37
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
2.4 DATA TRIANGULATION 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 PRIMARY INSIGHTS 40
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.6 RESEARCH ASSUMPTIONS 40
2.7 RISK ASSESSMENT 41

3 EXECUTIVE SUMMARY 42
FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 43
FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2022 VS. 2026 (USD MILLION) 43
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET 44
4 PREMIUM INSIGHTS 46
4.1 STEM CELL THERAPY MARKET OVERVIEW 46
FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH 46
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET 47
FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021 47
4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 47
FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES 48
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 49
5.2.1.1 Availability of funding for stem cell research 49
TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD) 49
FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS 49
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 50
5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities 50
TABLE 3 NEW GMP FACILITIES, 2017-2020 51
5.2.1.3 Increasing clinical trials for stem cell-based therapies 51
FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020) 51
FIGURE 22 CLINICAL TRIALS, BY PHASE 52
5.2.2 RESTRAINTS 52
5.2.2.1 Ethical concerns related to embryonic stem cells 52
5.2.2.2 High cost of cell-based research 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emergence of iPSCs as an alternative to ESCs 53
5.2.3.2 Growing demand for cell & gene therapies 53
5.2.4 CHALLENGES 53
5.2.4.1 Technical limitations associated with manufacturing processes 53

5.3 TECHNOLOGY ANALYSIS 54
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 54
5.4 VALUE CHAIN ANALYSIS 54
FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 55
5.5 ROLE IN ECOSYSTEM 56
FIGURE 24 ECOSYSTEM MARKET MAP 56
5.6 SUPPLY CHAIN ANALYSIS 56
FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 57
TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS 57
TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 58
5.7 PORTER’S FIVE FORCES ANALYSIS 58
5.7.1 THREAT OF NEW ENTRANTS 59
5.7.2 THREAT OF SUBSTITUTES 59
5.7.3 BARGAINING POWER OF SUPPLIERS 59
5.7.4 BARGAINING POWER OF BUYERS 59
5.7.5 INTENSITY OF COMPETITION RIVALRY 60
5.8 REGULATORY LANDSCAPE 60
5.8.1 NORTH AMERICA 60
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 60
5.8.2 EUROPE 62
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 62
5.8.3 ASIA PACIFIC 63
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 63
5.8.4 REST OF THE WORLD 65
TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 65
5.9 PRICING ANALYSIS 66
5.9.1 PRICING ANALYSIS 66
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS 66
5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT 66
5.10 PATENT ANALYSIS 67
FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020) 67
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 67
5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023) 67
TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023) 67
5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES 68
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 68
FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET 68
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 69
FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES 69

6 STEM CELL THERAPY MARKET, BY TYPE 70
6.1 INTRODUCTION 71
TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
6.2 ALLOGENEIC STEM CELL THERAPY 71
6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT 71
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 71
TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
6.3 AUTOLOGOUS STEM CELL THERAPY 73
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT 73
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7 STEM CELL THERAPY MARKET, BY CELL SOURCE 75
7.1 INTRODUCTION 76
TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 76
7.2 ADIPOSE TISSUE-DERIVED MSCS 76
7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET 76
TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 78
7.3 BONE MARROW-DERIVED MSCS 78
7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 78
TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS 80
7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET 80
TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
7.5 OTHER CELL SOURCES 82
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 84
8.1 INTRODUCTION 85
TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 85
8.2 MUSCULOSKELETAL DISORDERS 85
8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET 85
TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2020–2027 (USD MILLION) 86
TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3 WOUNDS & INJURIES 87
8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH 87
TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY REGION, 2020–2027 (USD MILLION) 87
TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88

8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 89
8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH 89
TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.5 SURGERIES 91
8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH 91
TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES,
BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.6 CARDIOVASCULAR DISEASES 92
8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH 92
TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.7 NEUROLOGICAL DISORDERS 94
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH 94
TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
8.8 OTHER THERAPEUTIC APPLICATIONS 96
TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 STEM CELL THERAPY MARKET, BY REGION 98
9.1 INTRODUCTION 99
TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 99
9.2 NORTH AMERICA 99
FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 100
TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 101
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 101
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 101
9.2.1 US 102
9.2.1.1 Rising approvals for stem cell therapy products to drive market 102
FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021) 102
TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 102
TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 103
9.2.2 CANADA 103
9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market 103
TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 104
TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 104
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 105
9.3 EUROPE 105
TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 106
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 106
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market 107
TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 107
TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 107
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 108
9.3.2 UK 108
9.3.2.1 Rising adoption of cell-based therapies to drive market 108
TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 109
TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 109
9.3.3 FRANCE 110
9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products 110
TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 110
TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 111
9.3.4 REST OF EUROPE 111
TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 111
TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 112
TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 113
FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 113
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 114
9.4.1 JAPAN 115
9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market 115
TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 115
TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 116
9.4.2 SOUTH KOREA 116
9.4.2.1 Favorable government support for stem cell therapy products to support market growth 116
TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 116
TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 117
9.4.3 INDIA 117
9.4.3.1 Rising cases of neurodegenerative disorders drive market 117
TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 118
TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 118
9.4.4 REST OF ASIA PACIFIC 119
TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 119
TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 120
9.5 REST OF THE WORLD 120
TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 121
TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 121
10 COMPETITIVE LANDSCAPE 122
10.1 INTRODUCTION 122
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 122
FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED 123
10.3 REVENUE SHARE ANALYSIS 123
10.4 MARKET SHARE ANALYSIS (2021) 124
10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS) 125
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 126
FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021) 127
10.6 COMPETITIVE BENCHMARKING 128
10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES 128
TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES 128
10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES) 129
TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES] 129
10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 130
10.7.1 PROGRESSIVE COMPANIES 130
10.7.2 STARTING BLOCKS 130
10.7.3 RESPONSIVE COMPANIES 130
10.7.4 DYNAMIC COMPANIES 130
FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021) 131
10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS 132
TABLE 115 COMPANY PRODUCT FOOTPRINT 132
10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS 133
TABLE 116 COMPANY REGIONAL FOOTPRINT 133
10.10 COMPETITIVE SCENARIO 134
TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS 134
TABLE 118 STEM CELL THERAPY MARKET: DEALS 134
11 COMPANY PROFILES 135
11.1 MAJOR PLAYERS 135
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 SMITH+NEPHEW 135
TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW 135
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021) 136
TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS 136
TABLE 121 SMITH+NEPHEW: DEALS 137
11.1.2 MEDIPOST CO., LTD. 138
TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW 138
FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019) 138
TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS 139
TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS 139
TABLE 125 MEDIPOST CO., LTD: DEALS 139
TABLE 126 MEDIPOST CO., LTD: OTHERS 139
TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS 140
11.1.3 JCR PHARMACEUTICALS CO., LTD. 141
TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW 141
FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021) 141
TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS 142
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 143
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 143
FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 143
TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS 144
TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS 144
TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS 144
11.1.5 ANTEROGEN. CO., LTD. 145
TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW 145
TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS 145
11.1.6 CORESTEM 146
TABLE 136 CORESTEM: BUSINESS OVERVIEW 146
TABLE 137 CORESTEM: PRODUCT OFFERINGS 146
TABLE 138 CORESTEM: REGULATORY APPROVALS 146
11.1.7 PHARMICELL CO., LTD. 147
TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW 147
TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS 147
TABLE 141 PHARMICELL CO., LTD.: DEALS 147
11.1.8 NUVASIVE, INC. 148
TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW 148
FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021) 149
TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS 149
11.1.9 RTI SURGICAL 150
TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW 150
TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS 150
11.1.10 ALLOSOURCE 151
TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW 151
TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS 151
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL 152
TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW 152
TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS 152
11.1.12 ORTHOFIX 153
TABLE 150 ORTHOFIX: BUSINESS OVERVIEW 153
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021) 154
TABLE 151 ORTHOFIX: PRODUCT OFFERINGS 154
11.1.13 STEMPEUTICS RESEARCH 155
TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW 155
TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS 155
11.1.14 REGROW BIOSCIENCES PVT LTD. 156
TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW 156
TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS 156
11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE) 157
11.2.1 ATHERSYS, INC. 157
11.2.2 MESOBLAST LTD 157
11.2.3 BIORESTORATIVE THERAPIES, INC. 158
11.2.4 PLURISTEM INC. 158
11.2.5 BRAINSTORM CELL LIMITED. 158
11.2.6 GAMIDA CELL 159
11.2.7 VIACYTE, INC. 159
11.2.8 KANGSTEM BIOTECH 159
11.2.9 HOPE BIOSCIENCES 160
11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG) 160
11.2.11 PERSONALIZED STEM CELLS 160
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 161
12.1 DISCUSSION GUIDE 161
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163
12.3 CUSTOMIZATION OPTIONS 165
12.4 RELATED REPORTS 165
12.5 AUTHOR DETAILS 166



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の幹細胞療法市場:種類別(同種、自家)、細胞源別、治療用途別(Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆